STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G/A] Akero Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Schedule 13G/A disclosure: Wellington Management Group LLP and related Wellington entities report beneficial ownership of 3,409,946 shares of Akero Therapeutics common stock, representing 4.28% of the class. The filing shows shared voting power of 2,924,691 shares and shared dispositive power of 3,409,946, with no sole voting or dispositive power. The securities are owned of record by clients of Wellington’s investment advisers rather than by Wellington itself.

The filing includes a certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer, consistent with a passive, institutional ownership disclosure under Schedule 13G/A.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Wellington reports a non-controlling institutional stake of 3.41M shares (4.28%), disclosed as held on behalf of clients.

The position size of 3,409,946 shares equates to 4.28% of Akero’s common stock as reported in the filing, below the 5% materiality threshold that typically triggers Schedule 13D scrutiny. The reporting shows shared voting power of 2,924,691 and shared dispositive power of 3,409,946, indicating control resides with client accounts rather than a single Wellington-controlled account. This is a routine, transparent disclosure by an investment adviser and holding-company group.

TL;DR: The filing documents passive, client-owned positions within Wellington’s adviser network and does not signal a control change.

Itemized cover-page data and Item 10 certification state the securities are held in the ordinary course of business and not for influencing control, which aligns with Schedule 13G/A usage. The filing also identifies the reporting persons as holding companies and investment-adviser entities and lists relevant subsidiaries and adviser affiliates. Because the stake is under 5% and voting/dispositive powers are shared, this disclosure is informational rather than governance-changing.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Wellington Management Group LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:08/12/2025
Wellington Group Holdings LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:08/12/2025
Wellington Investment Advisors Holdings LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:08/12/2025

FAQ

What stake does Wellington report in Akero Therapeutics (AKRO)?

Wellington reports beneficial ownership of 3,409,946 shares, representing 4.28% of Akero common stock.

How much voting power does Wellington share for AKRO?

The filing shows shared voting power of 2,924,691 shares and no sole voting power.

Does Wellington have sole dispositive power over the AKRO shares?

No. The filing reports 0 sole dispositive power and shared dispositive power of 3,409,946.

Are the AKRO shares held by Wellington or its clients?

The securities are owned of record by clients of the Wellington investment advisers, not directly by Wellington.

What type of SEC filing was submitted for AKRO?

The disclosure is an amendment to a Schedule 13G (Schedule 13G/A), indicating an institutional, non-control reporting regime.
Akero Therapeutics

NASDAQ:AKRO

AKRO Rankings

AKRO Latest News

AKRO Latest SEC Filings

AKRO Stock Data

4.47B
73.24M
1.14%
116.23%
11.11%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO